Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial

INTRODUCTION: Malignant peritoneal mesothelioma (MPM) is an uncommon but aggressive neoplasm and has a strong association with asbestos exposure. MPM has low survival rates of approximately 1 year even after (palliative) surgery and/or systemic chemotherapy. Recent advances in treatment strategies f...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMJ Open
Egile Nagusiak: de Boer, Nadine L, van Kooten, Job P, Burger, Jacobus W A, Verhoef, Cornelis, Aerts, Joachim G J V, Madsen, Eva V E
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2019
Gaiak:
Oncology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6530331/
https://ncbi.nlm.nih.gov/pubmed/31092657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-026779
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak